中文 | English
Return
Total: 7 , 1/1
Show Home Prev Next End page: GO
MeSH:(Iodized Oil/adverse effects/therapeutic use)

1.Cerebral Lipiodol Embolism after Transcatheter Arterial Chemoembolization of Hepatocellular Carcinoma.

Pil Jin CHUNG ; Seon Young PARK ; Young Il KIM ; Kyoung Won YOON ; Sung Bum CHO ; Sung Kyu CHOI ; Jong Sun REW

The Korean Journal of Gastroenterology 2009;54(2):130-134

2.Nodular hepatocellular carcinoma: treatment with intraarterial injection of I-131 Lipiodol.

Hyung Sik YOO ; Jung Ho SUH ; Jong Tae LEE ; Ki Whang KIM ; Dong Ik KIM ; Byung Soo KIM ; Heung Jai CHOI ; Kyung Sik LEE

Journal of Korean Medical Science 1990;5(2):75-83

3.Incidence and Risk Factors of Acute Hepatic Failure after Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma.

Sang Hoon JEON ; Kyung Sik PARK ; Young Hwan KIM ; Yo Sig SHIN ; Min Kyoung KANG ; Byoung Kuk JANG ; Woo Jin CHUNG ; Kwang Bum CHO ; Jae Seok HWANG

The Korean Journal of Gastroenterology 2007;50(3):176-182

4.Study on the efficacy and safety of high dose thymopentin combined with trans-artery chemoembolization for primary liver cancer.

Tao LI ; Zheng-Wen LI ; Hua-Chang WEN

Chinese Journal of Oncology 2007;29(12):941-942

5.Radiotherapy with (186)Re-lipiodol II for primary liver cancer patients.

Lehua SHI ; Zhifeng ZHANG ; Daoling ZHUANG ; Hongyan CHENG ; Yetao GAO ; Mengchao WU

Chinese Journal of Surgery 2002;40(11):814-816

6.Analysis of severe complications after transcatheter arterial chemoembolization for primary hepatocellular carcinoma.

Song-Nian LIANG ; Lin-Lin LIU ; Hong-Ying SU ; Bo FENG ; Guang-Sheng ZHAO ; Ke XU

Chinese Journal of Oncology 2008;30(10):790-792

7.Ginsenosides and dexamethasone in managing the liver injury and renal function after transcatheter arterial chemoembolization for hepatic carcinoma patient.

Ying-lu FENG ; Chang-quan LING ; Zhe CHEN ; Bai LI ; Wei GU

Chinese Journal of Oncology 2006;28(11):844-847

Sort by Result Analysis

Display Mode

Output Records




File Type





Total: 7 , 1/1 Show Home Prev Next End page: GO